GPC3 and neoplasm: In both orthotopic and subcutaneous xenograft models, ET58-DOTA-Gd produced tumor-specific signal enhancement, in terms of intensity as well as selective prolonged retention of signals in GPC3-positive xenografts but not in GPC3-negative xenografts.